News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ProStrakan Group Chooses RelayHealth for Approved Abstral REMS Program



1/20/2011 8:12:30 AM

(BUSINESS WIRE)--ProStrakan Group plc, an international pharmaceutical company based in the UK, has announced that it has chosen RelayHealth Pharmacy Solutions as its connectivity partner and McKesson Specialty Care Solutions to administer its U.S. Food and Drug Administration (FDA)-approved Abstral Risk Evaluation and Mitigation Strategy (REMS) program.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES